KRAS is involved in the sensitivity to anticancer agents in CRC, but FTD treatment has been reported to prolong survival independent of the presence of KRAS mutations [25], suggesting that KRAS was not involved in causing FTD resistance. The gene discussed is KRAS; the disease is colorectal carcinoma.